U.S. markets closed

Quanterix Corporation (QTRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.80-8.57 (-12.72%)
At close: 4:00PM EST

58.80 0.00 (0.00%)
After hours: 6:49PM EST

Sign in to post a message.
  • k
    kelly
    gez...it is down more than 21% in two days...
  • J
    Jay
    One competitor of Techne's Protein Simple business unit is Quanterix (QTRX, currently at 16.7 USD (first mentioned on this mb about 1 m ago, at ca 15 USD), MC 370m, EV 290m). Quaterix' SIMOA assay/technology allows for an increased sensitivity of 3 orders of magnitude of detecting proteins (and in future also RNA, DNA) in the blood. SIMOA (=single molecule array) allows to detect trget molecules at fg/ml level, due to the ability to trap molecules in femtoliter sized wells of its array, thus allowing for detection of single molecules. Why is this interesting? Because it allows for "non-invasive" measurement of molecules (proteins) in the blood at levels, which up to now could not be measured with conventional instruments (due to their lower sensitivity, ie at pg/ml -ng/ml level). Therefore, markers for pre-symptomatic diseases states can be followed, which up to now were not accessible. This is promising not only for academic R&D, but may -almost inescapably- play a prominent role in future drug trials, disease follow-up, etc. Neurology, with its blood brain barrier (BBB) is on of the most interesting fields: tiny elevations of brain derived proteins pex Nf-L, Tau, Beat amyloid...), which in a disease (especially at early/pre-symptomatic levels) are elevated in the spinal fluid can now be measured in the blood as well (at fg/ml levels), thus giving a new opening to doing R&D and clinical follow up of some of the most important neurological diseases, such as multiple sclerosis (MS), Alzheimer's (AD), brain concussion, etc. An recent publication in Brain shows the potential of the SIMOA technology in MS: Nf-L measurements in the blood correlated not only with disease activity, but also with brain and spinal cord atrophy up to 5 years later (brain atrophy and spinal cord atrophy are the most important predictors of disability in MS). Importantly, Nf-L measurements predicted disease course as well or better than brain-MRI does (and at lower costs). Taking the example of MS, it is likely that in future Nf-L SIMOA measurements will be "mandatory" not only for drug studies, but also in the clinical practice for monitoring patients and in the decision process whether to escalate treatment in a given MS- patient. Similar scenarios are likely in the dementias (pex AD).
    QTRX has a sound management team an BOD (including ex-Fisher Scientific and ex Bayer CEO M.Dekkers). It's growth has been accelerating (40-50%) and will do so even more in future due to increasing scientific publications, such as the Brain paper mentioned above. Revenue is:a) 40% consumables, 35% instruments; b) 60% US, 30% Europe, 10% Asia; c) 60% Pharma-Biotech, 40% Academia; d) 70% Neurology, 15% Oncology, the rest inflammation, cardiology etc; Head count is ca 150, whereof 40% in commercial/sales. Half year 2018 revenues were 16 m (vs 10.5 in the first half 2017) and the company expects to grow in the next couple of years by at least 40%. They are not yet cash flow positive. They have ca 60+ mill cash and no significant debt. The CEO owns ca 900'000 shares, Biomerieux 2 Mio shares. I think the path to success is quite clearly written, but it will be the long term story which is particularly interesting. post from 2 years ago by Dr. John
  • D
    DrrJohn
    Excellent fireside chat with Cowen's Doug Schenkel and CEO Hrusovsky. "A must" while the recording is not yet expired.

    Started buying QTRX at ca 15 USD, consider adding (soon) after the recent selloff to 65.

    Dr John
  • s
    stocktargetadvisor
    $QTRX
    Maintains SVB Leerink Outperform USD 75 » USD 85
    Target Raised by Canaccord Genuity Buy USD 86 » USD 90
  • P
    Pikachu
    this is next ILMN and I see one comment per 10 weeks lmao. so underfollowed
  • k
    kelly
    this one can go down to $55
  • R
    Ryan
    GTE ENERGY CALLS EXPLODING>>> GOEV will AAPL BID MUCH HIGHER AFTER CANOO SAID" NOT INTERESTED

    HYLN CIIC VGAC LAZR SKLZ APPZ IS NEXT TO EXPLODE LIKE CLWD HAS

    FWDG MTVX ELECTRIC SCOOTERS< MINI BIKES and ELECTRIC GO KARTS, being rented at tracks around the world soon
  • J
    John
    Some nice volume. I’m trying to figure out if something is brewing.
  • D
    DrrJohn
    Well, I guess the recent rise in the share price is related to the results of a study by researches from Lund/Sweden and Lilly. Their study, shown at the recent AAIC conference, showed, that -using Quanterix' SIMOA technology- blood p-Tau217 is as accurate, resp. more accurate in diagnosing Alzheimer's disease as serum and CSF pTau181 or MRI scan, which might simplify diagnosis and have a great impact on future AD-studies. pTau217 also identified asymptomatic "patients" who already had tangles and plaques in the brain, which is exactly the population you want to test in therapeutic studies.

    Dr John
  • D
    DrrJohn
    Unfortunately one cannot skip' n paste in on the Yahoo mb (anymore), ie texts which one has written somewhere else. For those interested, I wrote a blurb on Quanterix on the Yahoo- Bio-Techne message board (ticker symbol TECH). BioTechne's business unit ProteinSimple is a competitor of QTRX...(or vice versa)
    regards

    Dr John
  • J
    John
    I posted my opinion that the stock will reach 75 by year end and yahoo keeps deleting it ?
  • Y
    Yahoo Finance Insights
    Quanterix reached an all time high at 86.00
  • c
    capKirk
    Any news on this drop?
  • J
    Jay
    One competitor of Techne's Protein Simple business unit is Quanterix (QTRX, currently at 16.7 USD (first mentioned on this mb about 1 m ago, at ca 15 USD), MC 370m, EV 290m). Quaterix' SIMOA assay/technology allows for an increased sensitivity of 3 orders of magnitude of detecting proteins (and in future also RNA, DNA) in the blood. SIMOA (=single molecule array) allows to detect trget molecules at fg/ml level, due to the ability to trap molecules in femtoliter sized wells of its array, thus allowing for detection of single molecules. Why is this interesting? Because it allows for "non-invasive" measurement of molecules (proteins) in the blood at levels, which up to now could not be measured with conventional instruments (due to their lower sensitivity, ie at pg/ml -ng/ml level). Therefore, markers for pre-symptomatic diseases states can be followed, which up to now were not accessible. This is promising not only for academic R&D, but may -almost inescapably- play a prominent role in future drug trials, disease follow-up, etc. Neurology, with its blood brain barrier (BBB) is on of the most interesting fields: tiny elevations of brain derived proteins pex Nf-L, Tau, Beat amyloid...), which in a disease (especially at early/pre-symptomatic levels) are elevated in the spinal fluid can now be measured in the blood as well (at fg/ml levels), thus giving a new opening to doing R&D and clinical follow up of some of the most important neurological diseases, such as multiple sclerosis (MS), Alzheimer's (AD), brain concussion, etc. An recent publication in Brain shows the potential of the SIMOA technology in MS: Nf-L measurements in the blood correlated not only with disease activity, but also with brain and spinal cord atrophy up to 5 years later (brain atrophy and spinal cord atrophy are the most important predictors of disability in MS). Importantly, Nf-L measurements predicted disease course as well or better than brain-MRI does (and at lower costs). Taking the example of MS, it is likely that in future Nf-L SIMOA measurements will be "mandatory" not only for drug studies, but also in the clinical practice for monitoring patients and in the decision process whether to escalate treatment in a given MS- patient. Similar scenarios are likely in the dementias (pex AD).
    QTRX has a sound management team an BOD (including ex-Fisher Scientific and ex Bayer CEO M.Dekkers). It's growth has been accelerating (40-50%) and will do so even more in future due to increasing scientific publications, such as the Brain paper mentioned above. Revenue is:a) 40% consumables, 35% instruments; b) 60% US, 30% Europe, 10% Asia; c) 60% Pharma-Biotech, 40% Academia; d) 70% Neurology, 15% Oncology, the rest inflammation, cardiology etc; Head count is ca 150, whereof 40% in commercial/sales. Half year 2018 revenues were 16 m (vs 10.5 in the first half 2017) and the company expects to grow in the next couple of years by at least 40%. They are not yet cash flow positive. They have ca 60+ mill cash and no significant debt. The CEO owns ca 900'000 shares, Biomerieux 2 Mio shares. I think the path to success is quite clearly written, but it will be the long term story which is particularly interesting.
  • P
    Pikachu
    Adaptive Biotechnologies Corporation
    $adpt $gh $nstg $psnl $qtrx - Personalized medicine / life sciences is going to be very lucrative area in 2020s to invest in. I believe at least 2 of these are on its way to be 10x + bagger in a new decade.
  • Y
    Yahoo Finance Insights
    Quanterix reached an all time high at 90.36
  • k
    kelly
    friend introduced this one to me...what is the price I shall get in? Is it too high now?
  • R
    Ryan
    Pre Market Movers GOSS PRVB VIVO PSNL

    ALLK HRTX DNLI SHOULD MOVE HIGHER TODAY ALSO
  • Y
    Yahoo Finance Insights
    Quanterix reached an all time high at 77.00
  • Y
    Yahoo Finance Insights
    Quanterix reached an all time high at 55.93